UK Study Launches to Find New Drug Targets for Endometriosis Affecting 1 in 10 Women
Cyclana Bio's 500-patient PEMP study collects biopsies and menstrual fluid to uncover what drives endometriosis and identify new treatments.
Summary
Cyclana Bio has received UK approval to launch PEMP, a 500-patient observational study on endometriosis — a chronic inflammatory condition affecting one in ten women. Recruiting at Peterborough City Hospital and the Rosie Hospital in Cambridge, the study will collect tissue biopsies and menstrual fluid to build 3D cell models that mimic real disease conditions. Researchers aim to identify the causal mechanisms behind endometriosis, pinpoint new druggable targets, and determine whether a single therapy or personalized medicine approach is needed. Early findings point to the extracellular matrix as a key player in the disease. Funded by a £5M pre-seed round, this study could reshape how endometriosis is diagnosed and treated.
Detailed Summary
Endometriosis affects roughly one in ten women worldwide, yet effective, targeted treatments remain scarce. Cyclana Bio's newly approved PEMP study represents one of the most structured efforts to date to understand what biologically drives the condition and identify novel drug targets capable of addressing its root causes rather than just symptoms.
The 500-patient observational study, now recruiting at two UK NHS hospitals, will collect tissue biopsies and menstrual fluid from women with and without endometriosis. These samples will be used to construct physiologically relevant 3D in vitro models — a technique that better captures real tissue dynamics compared to traditional flat cell cultures. The goal is to map tissue-level differences and uncover causal mechanisms that have so far eluded researchers.
A particularly notable angle is the focus on the extracellular matrix — the structural scaffold surrounding cells — which Cyclana Bio's prior work has implicated in disease manifestation. Understanding how the extracellular matrix behaves differently in endometriosis tissue could open entirely new therapeutic avenues, including potential targets relevant to broader chronic inflammatory conditions.
The study also aims to develop patient stratification tools, recognizing that endometriosis likely isn't a single uniform disease. This could mean future treatments are tailored to individual biological profiles rather than applied as a one-size-fits-all approach — a shift toward precision medicine for a historically under-researched condition.
Caveats apply: PEMP is an observational study, so it will generate hypotheses and targets rather than prove treatment efficacy. Drug development from these findings remains years away. Still, for the millions of women living with endometriosis — a condition linked to chronic pain, infertility, and systemic inflammation — this research represents a meaningful step toward better, biologically grounded care.
Key Findings
- 500-patient UK study collecting biopsies and menstrual fluid to model endometriosis tissue in 3D lab systems
- Extracellular matrix identified as a potential key driver of endometriosis disease progression
- Study aims to find novel druggable targets and determine if personalized medicine is required
- Patient stratification tools will be developed to distinguish endometriosis subtypes for targeted therapy
- Methodology may extend to other chronic inflammatory conditions beyond endometriosis
Methodology
This is a news report summarizing a clinical study announcement from Longevity.Technology, a credible longevity-focused outlet. The study itself is an observational clinical trial with regulatory approval from the UK Health Research Authority and Research Ethics Committee, lending institutional credibility. No peer-reviewed data has been published yet; findings are anticipated from ongoing recruitment.
Study Limitations
This is a pre-results announcement; no clinical data or findings have been published yet, limiting current actionability. The study is observational, meaning it identifies associations and targets rather than testing treatments directly. Drug development from these targets would require additional years of preclinical and clinical validation before reaching patients.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.